Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.

🚀 Roche has recently entered into a collaboration with Oxford BioTherapeutics (OBT) to identify novel targets for antibody-based cancer therapies. The partnership includes an upfront payment of ...

(MENAFN- EIN Presswire) Partnership to accelerate development of Novel Small Extracellular Vesicle CNS Drug Delivery Platform and enhance Interactome Biotherapeutics' Pipeline OXFORD , UNITED ...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed38th cons ...

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 Bolt Biotherapeutics, Inc. Tue, Mar 25, 2025, 4:30 PM 4 min read ...

In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other best stocks to penny stocks that will skyrocket. On March 21, Jason D.

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

The 616 shareholders in attendance, who represented 77.03% of the total Roche Holding, Comcast, Eaton Corp and National Presto Industries are included in this Analyst Blog. Today's Research Daily ...

Investing.com -- Shares of Artiva Biotherapeutics Inc (NASDAQ:ARTV) climbed 2.5% as the company received positive comments from H.C. Wainwright analyst Edward White. The uptick in stock price ...

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et ...